5.42

3.39% -0.19

Kazia Therapeutics Limited Adr (KZIA)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$5.61

Offen:

$5.63

24-Stunden-Volumen:

13,554

Relative Volume:

0.10

Marktkapitalisierung:

$18.98M

Einnahmen:

Nettoeinkommen (Verlust:

$-13.52M

KGV:

-7.3243

EPS:

-0.74

Netto-Cashflow:

$-10.03M

1W Leistung:

+2.85%

1M Leistung:

-3.49%

6M Leistung:

+92.33%

1J Leistung:

-21.45%

1-Tages-Spanne:

$5.3688

$5.8731

1-Wochen-Bereich:

$4.30

$6.01

52-Wochen-Spanne:

$1.866

$15.80

Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile

Firmenname

Kazia Therapeutics Limited Adr

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

01161298780088

Adresse

140 WICKS RD, NEW SOUTH WALES 2113, NSW

Mitarbeiter

Twitter

@KaziaTx

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

KZIA's Discussions on Twitter

Vergleichen Sie KZIA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KZIA	5.3688	18.98M	0	-13.52M	-10.03M	-0.74
VRTX	449.64	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	748.66	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	589.18	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.13	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	106.50	24.89B	3.30B	-501.07M	1.03B	11.54

Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-10-14	Eingeleitet	Maxim Group	Buy
2021-01-05	Eingeleitet	H.C. Wainwright	Buy

Kazia Therapeutics Limited Adr Aktie (KZIA) Neueste Nachrichten

Nov 12, 2024

SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow

Nov 12, 2024

Nov 04, 2024

Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India

Nov 04, 2024

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan

Nov 04, 2024

Oct 30, 2024

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 30, 2024

Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 29, 2024

Oct 28, 2024

Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq

Oct 28, 2024

Oct 16, 2024

Ratios in Focus: Analyzing Kazia Therapeutics Limited ADR (KZIA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 16, 2024

Kazia Therapeutics Stock Scheduled to Reverse Split on Monday, October 28th (NASDAQ:KZIA) - Defense World

Oct 16, 2024

Oct 02, 2024

Paxalisib shows promise in brain metastasis treatment - Investing.com

Oct 02, 2024

It makes sense and dollars to buy Kazia Therapeutics Limited ADR (KZIA) stock - SETE News

Oct 02, 2024

Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex

Oct 02, 2024

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan

Oct 02, 2024

Oct 01, 2024